Indeed, the immune system is involved in the control of tumor progression at two opposite directions: on the one hand, it possesses an inhibitory effect on the development of the tumor via the activation of Th1 responses that are PKCθ-independent and on the other hand, it could promote the tumor invasion by activating the Th2 responses that are PKCθ-dependent [69]. The gene discussed is PRRT2; the disease is neoplasm.